The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.
The Centre for Process Innovation (CPI), a UK-based technology innovation center that provides services to small and medium-sized enterprises in the UK, has equipped the UK National Biologics Manufacturing Centre with Novasep’s BioSC Lab for protein purification. CPI’s services are intended to decrease time to market for novel products or processes. Within this framework, the CPI has been keen to introduce breakthrough continuous processes in the UK biopharmaceutical sector, CPI said in a press release. These technologies enable developers to reduce equipment footprint and increase process yields, thereby saving time and money.
“The National Biologics Manufacturing Centre has been designed to help companies of all sizes to develop, prove, and commercialize new and improved processes and technologies for biopharmaceutical manufacture,” said Chris Dowle, director of biologics at CPI, in the release. “The installation of Novasep’s BioSC Lab will be a valuable asset to customers using the centre."
Novasep’s continuous biochromatography equipment, BiosSC Lab, can purify a few grams of proteins per day. This enables users to develop cost-effective, high-yield production processes while maintaining the same quality attributes of the protein. The equipment is flexible and supports any process operating mode, including batch, parallel batch, and continuous. It is specifically designed to quickly provide the operator with the best operational parameters for purifying and converting a batch biochromatography recipe into a continuous, optimized one. Its simulation software, BioSC Predict, frees the process developer to set the most efficient mode and parameters to purify biomolecules such as monoclonal antibodies (mAbs), blood factors, and other proteins.
Source: Novasep
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.